| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
|
|---|
| Outline of Final Research Achievements |
In order to make in vitro disease model of TEN and SJS, we used three-dimensional epidermis (3D epidermis) from patient origin, patient’s own peripheral blood mononuclear cells (PBMC) and culprit drugs. As a result, we could not model these disorders, however, we have developed two methods as below: 1) we could reconstruct 3D epidermis using patient’s own plucked hair follicle derived keratinocytes, 2) we could proliferate drug or metabolite reactive PBMCs barely presented in peripheral blood. However, as there existed a case that could react neither culprit drug nor metabolite, we assumed that other factors (substances or cells etc.) might be necessary to activate PBMC in addition to culprit drugs and metabolites.
Moreover, as PBMC activated by culprit drug could not induce lethal injury of 3D epidermis, we suspected that epidermal damage arose in TEN/SJS patients might be caused by not only activated PBMC but other elements (substances or cells etc.).
|
